Financials in CAD. Standardized financial statements.
A compact view of how Medexus Pharmaceuticals Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $108.33M | $113.05M | $108.10M | $76.70M | $79.66M | $74.36M | $33.86M | $10.01M | $6.21M | $3.75M |
| Revenue Growth? | -4.2% | +4.6% | +40.9% | -3.7% | +7.1% | +119.6% | +238.3% | +61.3% | +65.5% | 0.0% |
| Cost of Revenue? | $51.75M | $53.54M | $48.06M | $38.77M | $37.66M | $22.99M | $10.38M | $4.97M | $2.08M | $998,427 |
| Gross Profit? | $56.58M | $59.51M | $60.04M | $37.93M | $42.01M | $29.44M | $20.14M | $5.04M | $3.40M | $2.45M |
| Gross Margin? | +52.2% | +52.6% | +55.5% | +49.4% | +52.7% | +39.6% | +59.5% | +50.4% | +54.9% | +65.4% |
| Operating Expenses? | $48.36M | $48.72M | $52.42M | $50.30M | $43.38M | $30.48M | $20.85M | $7.88M | $6.80M | $3.79M |
| Operating Income? | $8.22M | $10.79M | $7.61M | -$12.38M | -$1.38M | -$1.48M | -$706,000 | -$2.84M | -$3.40M | -$4.19M |
| EBITDA? | $16.81M | $19.28M | $14.65M | $14.55M | -$23.61M | $3.78M | $1.67M | -$2.06M | -$3.35M | -$4.04M |
| Income Before Tax | $1.44M | $106,000 | -$5.04M | -$3.82M | -$31.50M | -$7.36M | -$6.10M | -$3.48M | -$1.83M | -$2.30M |
| Income Tax Expense | -$807,000 | $320,000 | -$6.26M | -$941,000 | -$3.24M | -$1.12M | $222,000 | $0 | $0 | $0 |
| Net Income? | $2.25M | -$214,000 | $1.22M | -$2.88M | -$28.26M | -$4.70M | -$4.88M | -$3.48M | -$1.37M | -$2.30M |
| EPS? | $0.09 | $-0.01 | $0.08 | $-0.19 | $-1.86 | $-0.33 | $-0.48 | $-0.47 | $-0.28 | $-0.37 |
| Diluted EPS? | $0.08 | $-0.01 | $0.08 | $-0.19 | $-1.86 | $-0.33 | $-0.48 | $-0.47 | $-0.28 | $-0.37 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality